Positive. Eli Lilly and Company (LLY) is positioned for growth with strong potential for returns.

From Yahoo Finance: 2025-05-01 15:14:00

In a recent article, Eli Lilly and Company (NYSE:LLY) is compared to other growth stocks to buy for the next 3 years. Analysts like Dan Ives and Michael Darda express confidence in the tech sector, particularly AI, despite tariff concerns. Both predict strong returns from AI-related spending.

Eli Lilly and Company (NYSE:LLY) has seen success in the GLP-1 space, with plans to submit an oral GLP-1 agonist for approval in 2025 and 2026. Recent acquisitions and partnerships, including the most recent with Scorpion Therapeutics, have positioned the company for growth. Analysts maintain a positive outlook on LLY’s future performance.

Parnassus Core Equity Fund views Eli Lilly And Co. (NYSE:LLY) as a strong long-term investment due to its innovation and strong position in the pharmaceutical industry. Despite a recent decline in stock value, analysts are optimistic about LLY’s growth potential. LLY ranks 3rd on a list of best growth stocks, with high potential for future returns.

Looking beyond Eli Lilly and Company (NYSE:LLY), analysts suggest exploring undervalued AI stocks for potentially higher returns. While LLY shows promise, AI stocks are seen as holding greater potential for significant gains within a shorter time frame. Investors are encouraged to consider AI stocks for a promising investment opportunity.

Read more: Is Eli Lilly and Company (LLY) the Best Growth Stock to Buy for the Next 3 Years?